CORT — Corcept Therapeutics Incorporated

CORT — 오늘 왜 언급됐나 (2026-10-24)

• Genmab의 난소암 치료제 임상 3상 긍정적 결과 발표로 코셉트 주가가 급락했습니다.
• 이 결과는 코셉트의 신규 승인 약물 리포르리와 직접적인 경쟁 구도를 형성하게 했습니다.

Why people talked about CORT

• Corcept Therapeutics stock dropped significantly after Genmab reported positive late-stage trial results for its ovarian cancer drug.
• The new data positions Genmab's treatment as a strong competitor to Corcept's recently approved drug, Lifyorli.
• This competitive pressure coincided with insider selling activity by four executives at Corcept over the past week.